Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 44 (4), 183-9

Sorafenib: Complexities of Raf-dependent and Raf-independent Signaling Are Now Unveiled


Sorafenib: Complexities of Raf-dependent and Raf-independent Signaling Are Now Unveiled

Yasunobu Matsuda et al. Med Mol Morphol.


Hepatocellular carcinoma (HCC) is the most common primary cancer worldwide. The only current drug available for clinical treatment of HCC is sorafenib, which inhibits multiple signaling kinases including Raf family members, platelet-derived growth factor receptor, vascular endothelial growth factor receptors 1 and 2, c-Kit, and Fms-like tyrosine kinase 3. Many studies have revealed that the mechanism underlying the antitumor effect of sorafenib is complex. Because sorafenib inhibits C-Raf more potently than B-Raf, the therapeutic efficacy of sorafenib is strongly influenced by the relative expression and activity of B-Raf and C-Raf and the complex interactions between these factors. Moreover, Rafindependent signaling mechanisms have recently emerged as important pathways of sorafenib-induced cell death. Basic research studies have suggested that using sorafenib as part of a combination therapy may improve its effect, although this has yet to be confirmed by clinical evidence. Further studies of the functional mechanism of sorafenib are required to advance the development of targeted therapy for HCC. To aid future work on sorafenib, we here review the current literature pertaining to sorafenib signaling and its clinical efficacy in both monotherapy and combination therapy.

Similar articles

See all similar articles

Cited by 12 PubMed Central articles

See all "Cited by" articles


    1. Cancer Res. 2004 Oct 1;64(19):7099-109 - PubMed
    1. JAMA. 2010 Nov 17;304(19):2154-60 - PubMed
    1. Clin Cancer Res. 2010 Jan 15;16(2):390-7 - PubMed
    1. Semin Oncol. 2006 Aug;33(4):392-406 - PubMed
    1. J Gastroenterol. 2010 Aug;45(8):794-807 - PubMed

MeSH terms